Clinical trial
Safety Study of RAD001 to Treat Patients With Metastatic Kidney Cancer
NCT00446368 · The Methodist Hospital Research Institute, Other · Completed
Key facts
| NCT number | NCT00446368 |
|---|---|
| Title | Safety Study of RAD001 to Treat Patients With Metastatic Kidney Cancer |
| Official title | Phase II Study of RAD001 (Everolimus) in Patient's With Metastatic Renal Cell Cancer |
| Acronym | RAD001 |
| Lead sponsor | The Methodist Hospital Research Institute, Other |
| Collaborators | Novartis Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Renal Cell |
| Intervention type | Drug |
| Interventions | RAD001 |
| Enrollment | 66 |
| Start date | May 1, 2005 |
| Primary completion | Sep 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Mar 12, 2007 |
| Last update posted | Mar 17, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: